PharmaTelevision - Oxford BioMedica: Survival of the ‘Cash-Rich'

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Oxford BioMedica: Survival of the ‘Cash-Rich'

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Eighteen months in the life of a biotech company is a significant length of time. Nick Woolf takes this opportunity to bring you up-to-date with the changes in Oxford BioMedica since his last appearance on the show, giving insight into the Trovax® trial results and the effects of these results on its relationship with Sanofi-aventis. Looking to the future he tells of the restructuring the company has gone through in order to secure its financial and commercial position in these uncertain times and discusses the importance of their ‘cash-rich’ status.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Changes in Oxford BioMedica over the last 18 months

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here in London. On this show I have Nick Woolf, who is Chief Business Officer at Oxford BioMedica in Oxford, UK. Welcome to the show.

Nick Woolf:

Thanks very much Fintan it's a pleasure to be here.

Fintan Walton:

Nick, you were on the show about 18 months ago when we talked about Oxford BioMedica. 18 months as everybody knows in biotech is reasonably long time a lots of things have changed could you describe where Oxford BioMedica is now in relation to it was 18 months ago number of things you moved on particularly your products?

Nick Woolf:

Absolutely I mean the company is in a different position today then it was 18 months ago. We have still have a very strong partnership with Sanofi-aventis around our lead program TroVax and mean time we have moved forward some of our other programs in particular our Parkinson's Drug ProSavin which is now in clinical development. And we've also looked at our strategy and our management to ensure that we are well positioned as we go forward now to really drive Oxford BioMedica as quickly as possible towards sustainable profitability as a highly valid biopharmaceutical company.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Nick Woolf

Chief Executive Officer

Nick Woolf, Chief Business Officer of Oxford BioMedica, was appointed to the company's board in March 2005. He has extensive experience in investment banking and equity research in the biotechnology and pharmaceutical sectors and has been involved in all aspects of company financing, ranging from initial public offerings to major corporate deals. Nick joined Oxford BioMedica in 2002 from ABN AMRO, where he was a Director and Head of European Biotechnology Research. Prior to ABN AMRO, he was a Vice President and Senior European Biotechnology Analyst at Robertson Stephens, and was previously at both Nomura and SBC Warburg. Nick is a qualified FCCA accountant and holds an MA in Chemistry from the University of Oxford

Oxford BioMedica

Oxford BioMedica, a publically quoted biopharmaceutical company that specializes in the development and commercialization of innovative gene-based medicines, was founded in 1995 as a spin out from Oxford University. Oxford BioMedica has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems. They several products which use genes as the mediators of either a therapeutic effect or an immune response. The company's development pipeline is comprised of five gene-based product candidates. Of these products, TroVax, a therapeuticcancervaccine for multiple solid cancers, is being developed in collaboration with Sanofi-aventis and is currently in Phase III development for renal cancer. ProSavin is a gene-based treatment for Parkinson's disease entered a Phase I/II trial of ProSavin in December 2007. In addition to the TroVax collaboration with Sanofi-aventis, Oxford BioMedica has corporate collaborations with ARIUS Research, Intervet International, MolMed, Sigma-Aldrich, Viragen, VIRxSYS and Wyeth. In addition, the company has technology license agreements with Biogen Idec, GlaxoSmithKline, Merck & Co. and Pfizer.